• locale

  United States

• market

  PRIVATE

• industry

  Biotechnology and Pharmaceuticals

• website

  www.thetispharma.com/

Thetis Pharmaceuticals is a clinical-stage biopharmaceutical company developing TP-317, an oral Resolvin E1 drug, for treating mild-to-moderate inflammatory bowel disease (IBD) and solid tumors. The drug is a first-in-class, oral small molecule agonist of BLT1.